摘要
目的比较缬沙坦(Valsartan,Val)和贝那普利(Benazepril,Ben)治疗糖尿病肾病(DN)尿蛋白的效果。方法40例患者均符合下列诊断标准:①2型DM,按1997年ADA标准;②DN的诊断为尿清蛋白排泄(UAE)每天>300mg。随机分成两组:Val组和Ben组各20例。Val组:开始给予80mg,qd,口服。Ben组:开始予10mg,qd。血压(BP)以控制在130/80mmHg(1mmHg=0.133kPa)以下为目标。所有患者分别于治疗前和治疗8周后用放射免疫法测定24hUAE,并于整个过程中反复多次观测BP,根据BP控制情况,调整Val和Ben的药物剂量,必要时加服利尿剂。结果UAE用自然对数值表示Val组从6.81±0.41降至6.23±0.45,差异有显著性(P<0.01);Ben组从6.89±0.48降至6.31±0.51,差异有显著性(P<0.01)。治疗后,两组间比较,差异无显著性(P>0.05)。结论两组BP下降程度相似,UAE下降程度也相似(P>0.05),但Val组不良反应发生率少。
Objective To explore the effects of valsartan （Val） and benazepril （Ben） on urinary albumin excretion （UAE） in diabetic nephropathy （DN）. Methods 40 cases with DN （UAE 〉300mg/d） were randomly divided into two groups：（1）Val group consisted of 20 cases（8M/12F） , treated with Val 80 -160mg/day. （2）Ben group 20 cases （9M/11 F）, treated with Ben 10 -30mg/d. A goal of blood pressure （BP） control was 130/80mmHg or less in the two groups. Treatment period lasted for 8 weeks. The levels of UAE were measured by radioimmunoassay before and after treatment. We also measured Bp, fasting blood glucose, glycosylated hemoglobulin. Results After treatment of 8 weeks, Bp values in the two groups declined significantly compared with the pretreatment levels （P 〈 0.01 ）, but no statistical significant difference in the two groups was found （P 〉 0.05 ） . The levels of UAE in the two groups decreased significantly in comparison with pretreatment （P 〈0.01 ）. These results were converted into logarithmic values , expressed as （1）Val group 6.81±0.41 vs. 6.23 ±0.45. （2）Ben group 6.89 ± 0.48 vs, 6.31 ± 0.51, respectively. After 8 weeks therapy, Val and Ben have comparable effects on reducing UAE in DN （P 〉 0.05）. Val group seems to have lower adverse drug reaction rate. Conclusions The results indicate that Val has similar effects on reducing UAE in DN compared with Ben. And Val has fewer side effects.
出处
《医学研究杂志》
2007年第11期66-68,共3页
Journal of Medical Research
关键词
糖尿病肾病
缬沙坦
贝那普利
治疗
Diabetic nephropathy
Valsartan
Benazepril
Therapy
